Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04829955
Other study ID # Cardio eccentric protocol 3.5
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 29, 2022
Est. completion date December 12, 2023

Study information

Verified date April 2024
Source Vienna Hospital Association
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with ischemic cardiomyopathy and mildly reduced ejection fraction suffer from reduced functional capacity and fatigue caused by loss of muscle strength and reduced aerobic capacity. A few studies have shown that structured endurance and resistance training programs were able to improve walking capacity and limb strength. Although both concentric and eccentric training programs are beneficial for these patients, eccentric training is less stressful to the cardiovascular system. The aim of the study is to determine if eccentric-orientated body weight and manual resistance training in ischemic cardiomyopathy patients will lead to superior results compared to concentric training.


Description:

BACKGROUND: Eccentric resistance training demonstrated positive effects in ischemic cardiomyopathy patients in several studies. These studies were mainly set on device-based training interventions comparing eccentric-orientated and concentric-orientated training. Eccentric-orientated training induced comparable positive effects on cardiac and functional levels and even better effects on muscle strength improvement. RESEARCH AIMS: The aim of the study is to determine if eccentric-orientated body weight and manual resistance training in ischemic cardiomyopathy patients will allow a more significant improvement in maximum voluntary contraction force of the knee extensors compared to concentric training. In contrast to previous studies, these interventions will be set without use of training devices. In addition, changes in the muscle cross section of the quadriceps muscle will be calculated by skeletal muscle ultrasound. Functional changes and quality of life will be assessed using one minute sit to stand test, six minutes walking test and Kansas City Cardiomyopathy Questionnaire. Cardiac outcome parameters will be assessed by using body composition and hemodynamic parameters as well as echocardiography, laboratory values and specific biomarkers for sarcopenia / cachexia. METHODS: The investigators propose to run a monocentric, prospective, double arm, open, randomized controlled trial. Eccentric-orientated training will be delivered to 30 ischemic cardiomyopathy patients. These patients will be randomized into two groups at the beginning, followed by a 6-weeks observation phase (without intervention for internal quality control of the measurement parameters). The intervention-phase will consist of six weeks of three times weekly either eccentric or concentric-oriented training. Outcome measurements will take place after randomization, after 6 weeks of observation as well as after the intervention phase


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date December 12, 2023
Est. primary completion date December 12, 2023
Accepts healthy volunteers No
Gender All
Age group 45 Years to 85 Years
Eligibility Inclusion Criteria: - Male / female, 45-85a - Ischemic cardiomyopathy with mildly reduced ejection fraction (40 -50%) - Coronary heart disease Exclusion Criteria: - Acute coronary syndrome, myocarditis or pericarditis in the last 3 months - Cardiac decompensation in the last 3 months - Severe symptomatic heart failure NYHA IV (New York Heart Association) - Device - carrier (ICD= Intracardial Defibrillator, CRT= Cardiac Resynchronization Therapy, PM=Pacemaker) - Hemodynamically significant valvular disease - Symptomatic cardiac arrhythmia - Intractable, uncontrolled hypertension (repetitive blood pressure > 150/100) - Severe comorbidities, which lead to study exclusion by the investigator - Pregnancy / nursing

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Eccentric manual resistance training
Eccentric bodyweight resistance training
Concentric manual resistance resistance training
Concentric bodyweight resistance training

Locations

Country Name City State
Austria Klinik Ottakring Vienna

Sponsors (1)

Lead Sponsor Collaborator
Vienna Hospital Association

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary MVC of knee-extensors isometric Knee dynamometer Baseline
Primary MVC of knee-extensors isometric Knee dynamometer After 6 weeks of observation
Primary MVC of knee-extensors isometric Knee dynamometer After 6 weeks of training
Secondary Muscle cross section area of the quadriceps femoris muscle calculated by skeletal muscle ultrasound measurement Sonographic measurement Baseline
Secondary Muscle cross section area of the quadriceps femoris muscle calculated by skeletal muscle ultrasound measurement Sonographic measurement After 6 weeks of observation
Secondary Muscle cross section area of the quadriceps femoris muscle calculated by skeletal muscle ultrasound measurement Sonographic measurement After 6 weeks of training
Secondary Six- minutes walking test (6MWT) Measures the walking distance within 6 minutes. Baseline
Secondary Six- minutes walking test (6MWT) Measures the walking distance within 6 minutes. After 6 weeks of observation
Secondary Six- minutes walking test (6MWT) Measures the walking distance within 6 minutes. After 6 weeks of training
Secondary One-minute sit to stand test Measures sit to stand repetitions within one minute. Baseline
Secondary One-minute sit to stand test Measures sit to stand repetitions within one minute. After 6 weeks of observation
Secondary One-minute sit to stand test Measures sit to stand repetitions within one minute. After 6 weeks of training
Secondary Quality of life (QoL) Kansas City Cardiomyopathy questionnaire (KCCQ) In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. Baseline
Secondary Quality of life (QoL) Kansas City Cardiomyopathy questionnaire (KCCQ) In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. After 6 weeks of observation
Secondary Quality of life (QoL): questionnaire Kansas City Cardiomyopathy questionnaire (KCCQ) In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. After 6 weeks of training
See also
  Status Clinical Trial Phase
Terminated NCT04066738 - Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy N/A
Recruiting NCT03536052 - Ablation at Virtual-hEart pRedicted Targets for VT N/A
Enrolling by invitation NCT02930265 - Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy N/A
Completed NCT01215253 - Ranolazine Implantable Cardioverter-Defibrillator Trial Phase 3
Completed NCT04508608 - Scintigraphic Evaluation of Contractile and Coronary Reserve in Patients With Ischemic Cardiomyopathy
Recruiting NCT05888662 - Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT) N/A
Completed NCT03857906 - Evaluation of Prophylactic Use of a Preoperative IABP in High-Risk Coronary Artery Bypass Graft Surgery
Completed NCT02501811 - Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure Phase 2
Recruiting NCT02058771 - Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
Not yet recruiting NCT01946048 - Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy Phase 1
Terminated NCT01759212 - Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure. Phase 2/Phase 3
Not yet recruiting NCT01447069 - Use of Beta-agonists in Stable Severe Congestive Heart Failure N/A
Recruiting NCT00972114 - CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy Phase 1/Phase 2
Completed NCT00896142 - Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation) N/A
Recruiting NCT01076660 - Left Ventricular Structural Predictors of Sudden Cardiac Death
Completed NCT00305214 - MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients N/A
Completed NCT00305240 - MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients N/A
Active, not recruiting NCT00962364 - Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
Recruiting NCT05769036 - Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients N/A
Completed NCT03862339 - The SoundScar Study The SOUNDSCAR Study